VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

Feb 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-02-13

Reporting Person: Chodakewitz Jeffrey (EVP GMDA, CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-13	Common Stock	S	5122	$87.67	Disposed	122511	Direct

Footnotes

F1: Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.

F2: Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Open market sales reported on this line occurred at a weighted average price of $87.67 (range $87.30 to $88.22).